{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:55:22Z","timestamp":1790477722672,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,10,23]],"date-time":"2009-10-23T00:00:00Z","timestamp":1256256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The International Prognostic Scoring System (IPSS) and karyotype are useful tools for risk stratification in primary myelofibrosis (PMF). We examined the additional prognostic impact of red blood cell transfusion need among 254 consecutive patients (median age, 59 years). Sixty\u2010two patients (\u223c24%) required transfusions at diagnosis whereas 22 (\u223c9%) became transfusion\u2010dependent and 170 remained transfusion\u2010independent during the first year postdiagnosis; after a median follow\u2010up of 55 months, the respective median survivals were 35, 25, and 117 months (<jats:italic>P<\/jats:italic> &lt; 0.01). Multivariable analysis confirmed the IPSS\u2010 and karyotype\u2010independent prognostic weight of transfusion status. Among IPSS intermediate\u20101 risk patients, overall median survival of 82 months was modified to 60 or 118 months, based on presence or absence of transfusion need, respectively (<jats:italic>P<\/jats:italic> &lt; 0.01). The corresponding figures for intermediate\u20102\/high risk patients were 30 and 64 months (<jats:italic>P<\/jats:italic> &lt; 0.01). Documented causes of death did not include iron overload. We conclude that transfusion status in PMF downgrades or upgrades prognosis within specific IPSS categories; transfusion need is a marker of aggressive disease biology in PMF, as it is in myelodysplastic syndromes. Am. J. Hematol., 2010. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.21574","type":"journal-article","created":{"date-parts":[[2009,10,23]],"date-time":"2009-10-23T18:57:07Z","timestamp":1256324227000},"page":"14-17","source":"Crossref","is-referenced-by-count":51,"title":["Transfusion\u2010dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis\u2014prognostic relevance is independent of IPSS or karyotype"],"prefix":"10.1002","volume":"85","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Schwager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,22]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018879"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810069"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.47"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.141"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004273421706"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2864"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7356"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404948"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.11.004"},{"key":"e_1_2_1_15_2","article-title":"Mature survival data in young patients with primary myelofibrosis\u2014Survival gains in recent years","author":"Vaidya R","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01216.x"},{"key":"e_1_2_1_18_2","article-title":"The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: A prospective survey of 202 cases in Japan","author":"Hidaka T","journal-title":"Eur J Haematol, in press."},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-178541"},{"key":"e_1_2_1_20_2","first-page":"35","volume-title":"World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues.","author":"Thiele J","year":"2001"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1199"},{"key":"e_1_2_1_22_2","first-page":"20:168","article-title":"Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders","author":"Mcclure R","year":"2006","journal-title":"Leukemia"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405097"},{"key":"e_1_2_1_24_2","article-title":"International prognostic scoring system\u2010independent cytogetic risk categorization in primary myelofibrosis","author":"Hussein K","journal-title":"Blood"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21391"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21192"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.21574","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.21574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T02:56:09Z","timestamp":1700621769000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.21574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,22]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1002\/ajh.21574"],"URL":"https:\/\/doi.org\/10.1002\/ajh.21574","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,22]]}}}